The Company of Biologists

Table 1.

Summary of the expression of FGF target genes in tail cultures in the absence (DMSO control) and presence of either the FGFR1 inhibitor SU5402 or the MAPK inhibitor U0126

	Culture condition	Phase I	Phase II	Phase III	Phase inhibitor	n
*Lfng*
2 h	DMSO	33	39	28		18
	U0126	26	39	35		23
	SU5402	8	33	58		12
3 h	DMSO	40	40	20		5
	SU5402	28	18	55		40
4 h	DMSO	33	33	33		15
	SU5402	10	20	70		40
6 h	DMSO	40	30	30		10
	SU5402	6	12	82		17
*Axin2*
2 h	DMSO	33	33	33	0	21
	SU5402	0	5	10	85	20
3 h	DMSO	30	40	30	0	10
	SU5402	0	0	0	100	14
4 h	DMSO	33	33	33	0	3
	SU5402	0	0	0	100	9

	Culture condition	Phase I	Phase II	Phase III	Phase inhibitor	n
*Lfng*
2 h	DMSO	33	39	28		18
	U0126	26	39	35		23
	SU5402	8	33	58		12
3 h	DMSO	40	40	20		5
	SU5402	28	18	55		40
4 h	DMSO	33	33	33		15
	SU5402	10	20	70		40
6 h	DMSO	40	30	30		10
	SU5402	6	12	82		17
*Axin2*
2 h	DMSO	33	33	33	0	21
	SU5402	0	5	10	85	20
3 h	DMSO	30	40	30	0	10
	SU5402	0	0	0	100	14
4 h	DMSO	33	33	33	0	3
	SU5402	0	0	0	100	9

Percentage of tails in Phases I, II and III are given for each combination at 2, 3, 4 and 6 hours. For Axin2, which shows an abnormal expression pattern after inhibitor treatment (data not shown), an additional column(Phase inhibitor) is introduced.

View Large

This Feature Is Available To Subscribers Only